ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Dichotomous T-Cell Repopulation after Anti-Thymocyte Globulin Induction Therapy in High Immunological Risk and DCD Renal Transplant Recipients

S. Telfer, S. Ullah, T. Fear, A. Mok, A. Jevnikar, P. Luke, A. Sener

Department of Surgery, Western University, London, ON, Canada
Schulich School of Medicine, Western University, London, ON, Canada
Department of Microbiology and Immunology, Western University, London, ON, Canada
Department of Nephrology, Western University, London, ON, Canada
Matthew Mailing Centre for Translational Transplant Studies, Western University, London, ON, Canada

Meeting: 2013 American Transplant Congress

Abstract number: A634

Background:

T-cell suppression through induction therapy is routinely used to promote graft survival in high immunological risk (HR) and donation after cardiac death (DCD) renal transplant recipients. Depletional therapy with anti-thymocyte globulin (ATG) initially leads to lymphopenia. The immune system however, has the capacity to repopulate the T-cell compartment. The T-cell response post ATG induction has not been characterized in HR and DCD recipients, who often have increased rates of rejection despite adequate immune suppression. Understanding this response is critical for optimizing early immune therapies.

Objective:

To establish the dynamics of T-cell reconstitution in DCD and HR recipients after ATG induction.

Methods/Results:

Reconstitution and proliferation rates of recipient (HR n=10 and DCD n=10) T-cell subsets were analyzed by 13-colour flow cytometry for 6 months post induction therapy with ATG. Following ATG, there was a rapid decline in the frequency of T-cells in both groups. Levels remained depressed for over 28 d. In HR patients, there was a rapid surge in the frequency of CD4 naive T-cells, which was not observed in DCD recipients. Although we observed significant proliferation in the effector memory phenotype in both HR and DCD patients, the response in the DCD cohort was blunted. Regulatory T-cells showed a surge in proliferation rates, however the magnitude of change was not as great in the DCD group. Immune reactivity, assessed using the ImmuKnow® assay, revealed CD4 T-lymphocytes were less immune-reactive in the DCD group.

Conclusion:

This preliminary study provides perspective on the effects of ATG on the T cell response at an early period following renal transplantation in two important and rapidly growing populations of recipients (HR and DCD). Initial data suggests there is a lack of significant homeostatic proliferative response in DCD recipients following ATG. Moreover, data suggests that CD4-lymphocytes may be less reactive in the DCD group. These observations suggest that ATG may be an overly aggressive approach in DCD recipients.

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Telfer S, Ullah S, Fear T, Mok A, Jevnikar A, Luke P, Sener A. Dichotomous T-Cell Repopulation after Anti-Thymocyte Globulin Induction Therapy in High Immunological Risk and DCD Renal Transplant Recipients [abstract]. Am J Transplant. 2013; 13 (suppl 5). https://atcmeetingabstracts.com/abstract/dichotomous-t-cell-repopulation-after-anti-thymocyte-globulin-induction-therapy-in-high-immunological-risk-and-dcd-renal-transplant-recipients/. Accessed May 14, 2025.

« Back to 2013 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences